Part 2 of 4: My guest today is Cyriac Roeding, founder, investor, and CEO of Earli, a company on a mission to transform cancer into a manageable condition. Using innovative gene therapy approaches, Earli’s technology forces cancer cells to produce a synthetic, non-human biomarker—overcoming the limitations of relying on naturally occurring biomarkers that cancer may or may not provide. Cyriac is a serial entrepreneur and investor who has created ventures at the intersection of physical and digital worlds. He has invested in startups like OpenAI and served as CEO of Shopkick, which was acquired for $250 million. His current focus, Earli, has raised nearly $60 million from top investors. Cyriac's journey from launching his first startup at 15 to being named a World Economic Forum Tech Pioneer showcases his valuable insights into building successful startups.